NCT00796731 - SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

LymphomaNon-Hodgkin

Interventions

DRUG

SAR3419

administered by intravenous infusion

Trial Locations (6)

Sanofi-Aventis Investigational Site Number 250005, Rennes

Sanofi-Aventis Investigational Site Number 250006, Lille

Sanofi-Aventis Investigational Site Number 250001, Pierre-Bénite

Sanofi-Aventis Investigational Site Number 250003, Rouen

Sanofi-Aventis Investigational Site Number 250004, Créteil

Sanofi-Aventis Investigational Site Number 250002, Villejuif